ZVRA
Zevra Therapeutics, Inc.+$0.16 (1.58%) At close $10.26 · Today
☾After Hours +$0.42 (4.04%) Nov 3, 7:59 PM ET
About ZVRA
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
Company
- Headquarters
- Boston, MA
- Employees
- 61 (2026)
- Listed
- Apr 16, 2015
- Exchange
- Nasdaq
- Website
- zevra.com
- SEC industry
- Pharmaceutical Preparations
- Cylvex sector
- Health Care · Pharmaceuticals
Pharmaceuticals
- Market cap #160 of 430
- P/B #154 of 396
Ranked highest first among stocks Cylvex covers.
- LLYEli Lilly and Company$1.26T-0.11%
- JNJJohnson & Johnson$640.8B-1.62%
- ABBVAbbVie Inc$505.4B-0.98%
- MRKMerck & Co Inc$356.9B-2.49%
- NVSNovartis AG$300.8B-1.40%
Financial summary
Related companies
About
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
From company filings and market data · Not investment advice
Price data
52W range and average volume from daily bars (unadjusted, last 252 sessions).
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.